Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;16(1):18-31.
doi: 10.1631/jzus.B1400184.

MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential

Wei Wang  1 , Yun-ping Luo
Affiliations
Review

MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential

Wei Wang et al. J Zhejiang Univ Sci B. 2015 Jan.

Abstract

MicroRNAs (miRs) are small single-stranded RNA molecules, which function as key negative regulators of post-transcriptional modulation in almost all biological processes. Abnormal expression of microRNAs has been observed in various types of cancer including breast cancer. Great efforts have been made to identify an association between microRNA expression profiles and breast cancer, and to understand the functional role and molecular mechanism of aberrant-expressed microRNAs. As research progressed, 'oncogenic microRNAs' and 'tumor suppressive microRNAs' became a focus of interest. The potential of candidate microRNAs from both intercellular (tissue) and extracellular (serum) sources for clinical diagnosis and prognosis was revealed, and treatments involving microRNA achieved some amazing curative effects in cancer disease models. In this review, advances from the most recent studies of microRNAs in one of the most common cancers, breast cancer, are highlighted, especially the functions of specifically selected microRNAs. We also assess the potential value of these microRNAs as diagnostic and prognostic markers, and discuss the possible development of microRNA-based therapies.

Keywords: Breast cancer; Diagnosis marker; MicroRNA; MicroRNA-based therapy; Oncogene; Tumor suppressors.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethics guidelines: Wei WANG and Yun-ping LUO declare that they have no conflict of interest.

This article does not contain any studies with human or animal subjects performed by any of the authors.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahmad A, Aboukameel A, Kong DJ, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011;71(9):3400–3409. doi: 10.1158/0008-5472.CAN-10-0965. - DOI - PMC - PubMed
    1. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. PNAS. 2003;100(7):3983–3988. doi: 10.1073/pnas.0530291100. - DOI - PMC - PubMed
    1. Andorfer CA, Necela BM, Thompson EA, et al. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med. 2011;17(6):313–319. doi: 10.1016/j.molmed.2011.01.006. - DOI - PubMed
    1. Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57(1):84–91. doi: 10.1373/clinchem.2010.151845. - DOI - PubMed
    1. Barh D, Malhotra R, Ravi B, et al. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol. 2010;17(1):70–80. doi: 10.3747/co.v17i1.356. - DOI - PMC - PubMed

Publication types

  NODES
Association 1
twitter 2